Newsletter | September 21, 2026

09.21.26 -- Should R&D Be Organized Around The Therapy, Not The Drug?

FEATURED ARTICLE

When Should R&D Organize Around The Therapy, Not Just The Drug?

Deciding whether a drug candidate should be developed as part of a combination or not should hinge on available evidence and a company’s therapeutic hypothesis. 

 

INDUSTRY INSIGHTS

 

When Clinical Trials Span Borders, Participants Shouldn't Cross Alone

Discover how human-centered support reduces barriers in global research. By prioritizing empathy and logistics, you can improve the participant experience and boost study outcomes.

 

4 Proven Strategies To Optimize Patient Enrollment, Avoid Rescue Trials

Though rescue studies are common, there are ample tactics to avoid these situations altogether, including robust planning, data analysis, and prioritization of patient recruitment and retention.

 

Shifting Left In Software Development: Reducing Risk Through Early Testing

In today’s development landscape, where speed and resilience must go hand in hand, adopting a "Shift Left" mindset transforms testing from a bottleneck into a catalyst for innovation.

 

Eliminating Barriers To In Vivo And Ex Vivo CAR-T Delivery

Learn how lentiviral vector processes evolve for in vivo and ex vivo CAR‑T—covering yield, purity, scalability, and shifting regulatory demands for safe, consistent systemic delivery.

 

Examining The New Look For Biotech

According to a recent episode of Citeline’s podcast series, “Small Biotechs, Big Decisions,” biotech is developing a new look that is leaner and savvier when it comes to working with partners.

 

Lyophilization: Protecting And Preserving Biologics

Uncover how lyophilization revolutionizes biologic drug manufacturing and ensures potent, stable treatments for complex diseases.

Connect With Life Science Leader: